In silico Design of Discontinuous Peptides Representative of B and T-cell Epitopes from HER2-ECD as Potential Novel Cancer Peptide Vaccines |
Manijeh, Mahdavi
(Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences)
Mehrnaz, Keyhanfar (Department of Biotechnology, Faculty of Advanced Sciences and Technologies, University of Isfahan) Violaine, Moreau (UMR 3145 SysDiag CNRS/Bio-Rad) Hassan, Mohabatkar (Department of Biotechnology, Faculty of Advanced Sciences and Technologies, University of Isfahan) Abbas, Jafarian (Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences) Mohammad, Rabbani (Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences) |
1 | Correa I, Plunkett T (2001). Update on HER-2 as a target for cancer therapy HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res, 3, 399-403. DOI ScienceOn |
2 | Disis M, Schiffman K (2001). Cancer vaccines targeting the HERZ/neu oncogenic protein. Sem Oncol, 28, 12-20. DOI |
3 | Dakappagari NK, Douglas DB, Triozzi PL, et al (2000). Prevention of mammary tumors with a chimeric Her-2 B-cell epitope peptide vaccine. Cancer Res, 60, 3782-9. |
4 | Dakappagari NK, Pyles J, Parihar R, et al (2003). Multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol, 170, 4242-53. DOI |
5 | De Groot AS, Cohen T, Ardito M, et al (2010). Use of bioinformatics to predict MHC ligands and T-cell epitopes: application to epitope-driven vaccine design. Methods Microbiol, 37, 35-66. DOI |
6 | Donnes P, Elofsson A (2002). Prediction of MHC class I binding peptides, using SVMHC. BMC Bioinformatics, 3, 25. DOI |
7 | Doytchinova IA, Flower DR (2002). Quantitative approaches to computational vaccinology. Immunol Cell Biol, 80, 270-9. DOI ScienceOn |
8 | Firat H, Garcia-Pons F, Tourdot S, et al (1999). H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol, 29, 3112. DOI |
9 | Fisher RD, Ultsch M, Lingel A, et al (2010). Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine. J Mol Biol, 402, 217. DOI ScienceOn |
10 | Kobayashi H, Wood M, Song Y, Appella E, Celis E (2000). Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res, 60, 5228-36. |
11 | Kastenmuller W, Gasteiger G, Gronau JH, et al (2007). Cross-competition of CD8+T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med, 204, 2187. DOI ScienceOn |
12 | Kennedy R, Celis E (2008). Multiple roles for CD4+ T cells in antitumor immune responses, Immunol Rev, 222, 129. DOI ScienceOn |
13 | Kobayashi H, Celis E (2008). Peptide epitope identification for tumorreactive CD4 T cells. Cur Opin Immunol, 20, 221. DOI ScienceOn |
14 | Kulkarni-Kale U, Bhosle S, Kolaskar AS (2005). CEP: a conformational epitope prediction server. Nucleic Acids Res, 33, 168-71. |
15 | Kumar S, Hinks JA, Maman JC, et al (2011). p185, an immunodominant epitope, is an autoantigen mimotope. J Bio Chem, 286, 26220. DOI ScienceOn |
16 | Lax I (1988). Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Biol, 8, 1831-4. |
17 | Lebreton A, Moreau V, Lapalud P, et al (2011). Discontinuous epitopes on the C2 domain of coagulation Factor VIII mapped by computer-designed synthetic peptides. Bri J Haematol, 155, 487-97. DOI ScienceOn |
18 | Li GF, Wang Y, Zhang ZS (2005). Identification of immunodominant Th1-type T cell epitopes from Schistosoma japonicum 28 kDa glutathione-Stransferase, a vaccine candidate. Acta Biochim Biophys Sin, 37, 751-8. DOI ScienceOn |
19 | Nair S, Kukreja N, Singh BP, Arora N (2011). Identification of B cell epitopes of alcohol dehydrogenase allergen of Curvularia lunata. PLoS ONE, 6, 20020. DOI |
20 | Mahdavi M, Mohabatkar H, Keyhanfar M, Jafarian Dehkordi A, Rabbani M (2012). Linear and conformational B cell epitope prediction of HER 2 ECD-subdomain III by in silico methods. Asian Pac J Cancer Prev, 13, 3053. 과학기술학회마을 DOI ScienceOn |
21 | Maupetit J, Derreumaux P, Tuffery P (2009). PEP-FOLD: an online resource for de novo peptide structure prediction. Nucleic Acids Res, 37, 498-503. DOI ScienceOn |
22 | Moreau V, Fleury C, Piquer D, et al (2008). PEPOP: computational design of immunogenic peptides. BMC Bioinformatics, 9, 71. DOI ScienceOn |
23 | Noguchi M, Sasada T (2013). Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother, 62, 919-29. DOI ScienceOn |
24 | Parker KC, Bednarek MA, Coligan JE (1994). Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol, 152, 163. |
25 | Pellequer JL, Westhof E, Van Regenmortel MH (1994). Epitope prediction from primary structure of proteins. In Peptide Antigens: A Practical Approach. GB Wisdow ed. Oxford, IRL Press. |
26 | Rammensee HG, Bachmann J, Emmerich NN, Bachor OA, Stevanovic S (1999). SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics, 50, 213-9. DOI |
27 | Ripoll DR (1992). Conformational study of a peptide epitope shows large preferences for beta-turn conformations. Int J Pept Protein Res, 40, 575-81. |
28 | Rosenberg S (2001). Progress in human tumor immunology and immunotherapy. Nature, 411, 380-4. DOI ScienceOn |
29 | Roggen EL (2008). B-cell epitope engineering: a matter of recognizing protein features and motives. Drug Discovery Today: Technologies, 5, 49-55. DOI ScienceOn |
30 | Singh H, Raghava GPS (2001). ProPred: Prediction of HLA-DR binding sites. Bioinformatics, 17, 1236-7. DOI ScienceOn |
31 | Senpuku H, Kato H, Takeuchi H, Noda A, Nisizawa T (1997). Identification of core B cell epitope in the synthetic peptide inducing cross inhibiting antibodies to surface protein antigen of streptococcus mutans. Immunol invest, 26, 531-48. DOI |
32 | Singh AK, Rathb SK, Misraa K (2011). Identification of epitopes in Indian human papilloma virus 16 E6: A bioinformatics approach. J Vir Methods, 177, 26-30. DOI ScienceOn |
33 | Siyi H, Zhiqiang Z, Liangwei L, et al (2008). Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Proteins, 70, 938-49. |
34 | Tai W, Mahato R, Cheng K (2010). The role of HER2 in cancer therapy and targeted drug delivery. J Control Rel, 146, 264-75. DOI ScienceOn |
35 | Van Regenmortel MH (1996). Mapping epitope structure and activity: from onedimensional prediction to four-dimensional description of antigenic specificity. Meth, 9, 465. DOI ScienceOn |
36 | Vita R, Zarebski L, Greenbaum JA, et al (2010). The immune epitope database 2.0. Nucleic Acids Res, 38, 854-62. DOI ScienceOn |
37 | Weber CA, Mehta PJ, Ardito M, et al (2009). T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv Drug Delivery Rev, 61, 965-76. DOI ScienceOn |
38 | Wallecha A, Ramos K, Malinina I, Singh R (2012). Listeria monocytogenes-based bivalent Lm-LLO immunotherapy for the treatment of HER2/neu positive and triple negative breast cancer and its impact on immunosuppression. Cancer Research, 72, 4-5. DOI |
39 | Zaks TZ, Rosenberg SA (1998). Immunization with a peptide epitope from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res, 58, 4902-8. |
40 | Wang B, Kaumaya PTP, Cohn DE (2010). Immunization with synthetic VEGF peptides in ovarian cancer. Gyn Oncol, 119, 564-70. DOI ScienceOn |
41 | Wiwanitkit V (2007). Predicted epitopes of Lig A of Leptospira interrogans by bioinformatics method: a clue for further vaccine development. Vaccine, 25, 2768-70. DOI ScienceOn |
42 | Awada A, Bozovic-Spasojevic I, Chow L (2012). New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? Cancer Treatment Reviews, 38, 494-504. DOI ScienceOn |
43 | Bian H, Reidhaar-Olson JF, Hammer J (2003). The use of bioinformatics for identifying class II-restricted T-cell epitopes. Meth, 29, 299-309. DOI ScienceOn |
44 | Alvarenga L, Moreau V, Felicori L, et al (2010). Design of antibody-reactive peptides from discontinuous parts of scorpion toxins. Vaccine, 28, 970-80. DOI ScienceOn |
45 | Ansari HR, Raghava GP (2010). Identification of conformational B-cell Epitopes in an antigen from its primary sequence. Immunol Res, 6, 6. |
46 | Axelsena TV, Holma A, Christiansena G, Birkelund S (2011). Identification of the shortest AB-peptide generating highly specific antibodies against the C-terminal end of amyloid-B42. Vaccine, 29, 3260-9. DOI ScienceOn |
47 | Calabrich A, Fernandes GS, Katz A (2008). Trastuzumab: mechanisms of resistance and therapeutic opportunities. Oncol, 22, 1250-8. |
48 | Chen SW, Van Regenmortel MH, Pellequer JL (2009). Structure-activity relationships in peptide-antibody complexes: implications for epitope prediction and development of synthetic peptide vaccines. Curr Med Chem, 16, 953. DOI ScienceOn |
49 | Cho HS, Mason K, Ramyar KX, et al (2003). Structure of the extracellular region of HER2 alone and in complex with the herceptin fab. Nature, 421, 756-60. DOI ScienceOn |
50 | Franklin MC, Carey KD, Vajdos FF, et al (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell, 5, 317-28. DOI ScienceOn |
51 | Gritzapis AD, Fridmanb A, Pereza SA, et al (2010). HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties. Vaccine, 28, 162-70. |
52 | Garrett JT, Kaumaya P, Pei D, Dalbey R, Magliery T (2007). Peptide based B cell epitope vaccines targeting HER-2/Neu. PhD thesis. Ohio State University, Ohio, USA. |
53 | Goede A, Jaeger IS, Preissner R (2005). SUPERFICIAL-Surface mapping of proteins via structure-based peptide library design. BMC Bioinformatics, 6, 223. DOI ScienceOn |
54 | Gritzapis AD, Voutsas IF, Lekka E, et al (2008). Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties. J Immunol, 181, 146-54. DOI |
55 | Guan P, Doytchinova IA, Zygouri C, Flower DR (2003). MHCPred: a server for quantitative prediction of peptide-MHC binding. Nucleic Acids Res, 31, 3621-4. DOI ScienceOn |
56 | Haste Andersen P, Nielsen M, Lund O (2006). Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci, 15, 2558-67. DOI ScienceOn |
57 | Jacot W, Fiche M, Zaman K (2013). The HER2 amplicon in breast cancer: topoisomerase IIA and beyond. Biochim Biophys Acta (BBA), 1836, 146-57. |
58 | Kageyama S, Kitano S, Hirayama M, et al (2008). Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci, 99, 601. DOI ScienceOn |
59 | Gangwara RS, Shil P, Sapkala GN, Khanc SA, Gore MM (2012). Induction of virus-specific neutralizing immune response against West Nile and Japanese encephalitis viruses by chimeric peptides representing T-helper and B-cell epitopes. Vir Res, 163, 40-50. DOI ScienceOn |
60 | Chen P, Rayner S, Hu KH (2011). Advances of bioinformatics tools applied in virus epitopes prediction. Virologica Sinica, 26, 1. DOI ScienceOn |
61 | Arensa R, Hallb TV, van der Burgb SH (2013). Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Sem Immunol, 25, 182-90. DOI ScienceOn |
62 | Thompson JD, Higgins DG, Gibson TJ (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res, 22, 4673. DOI ScienceOn |
63 | Miyako H, Kametani Y, Katano I, et al (2011). Antitumor effect of new HER2 peptide vaccination based on B cell epitope. Anticancer Res, 31, 3361-8. |